Pyxis Oncology Inc (PYXS) Stock Analysis

Pyxis Oncology Inc (PYXS) is a publicly traded company in the HEALTHCARE sector. It trades at $1.71, carries a market capitalization of $113.72M. This page summarizes the public market data, fundamentals, and frequently asked questions for PYXS, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Pyxis Oncology Inc currently has a Bullish sentiment score of 0.42.

About Pyxis Oncology Inc

Pyxis Oncology, Inc. is a preclinical biotechnology firm based in Cambridge, Massachusetts, focused on advancing innovative therapies for cancer treatment through the development of antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs). With a commitment to harnessing the power of targeted therapies, Pyxis aims to enhance the efficacy and safety profiles of oncology treatments, addressing unmet medical needs in the oncology landscape. The company's cutting-edge research and strateg...

GNG Research Analysis

GNG Research scores Pyxis Oncology Inc (PYXS) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for PYXS.

Frequently Asked Questions

Does PYXS pay dividends?

Pyxis Oncology Inc (PYXS) does not currently pay a regular dividend.

What is PYXS's market cap?

Pyxis Oncology Inc (PYXS) has a market capitalization of $113.72M with a current stock price of $1.71.